Search alternatives:
wt decrease » _ decrease (Expand Search), nn decrease (Expand Search), awd decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 wt » _ wt (Expand Search), 5 ht (Expand Search)
wt decrease » _ decrease (Expand Search), nn decrease (Expand Search), awd decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 wt » _ wt (Expand Search), 5 ht (Expand Search)
-
12021
-
12022
Data_Sheet_1_Long-term effects of the gait treatment using a wearable cyborg hybrid assistive limb in a patient with spinal and bulbar muscular atrophy: a case report with 5 years...
Published 2023“…Thus, this study aimed to investigate the long-term effects of the continued gait treatment with HAL in a patient with SBMA.</p>Results<p>A 68-year-old man with SBMA had lower limb muscle weakness and atrophy, gait asymmetry, and decreased walking endurance. …”
-
12023
-
12024
-
12025
-
12026
-
12027
Transitioning of people with T1D from Multiple Daily Injections (MDI) and Self-Monitoring of Blood Glucose (BGM) directly to MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) system...
Published 2022“…</p> <p>Results: 41 participants were recruited and randomized to either the AHCL (20) or the MDI+BGM (21) group. 37 participants (age 40.3±8.0 years; duration of diabetes 17.3 ± 12.1 years; BMI 25.1±3.1 kg/m2; HbA1c 7.2% ± 1.0) completed the study. Time spent in target (TIR) increased from 69.3±12.3% at baseline to 85.0±6.3% at 3 months in the AHCL group, while remaining unchanged in the control group: treatment effect 21.5% [95% CI 15.7, 27.3%]; p < 0.001. …”
-
12028
<b>Predictors of initial and sustained glycemic and weight response to tirzepatide: a post hoc analysis of SURPASS-4</b>
Published 2025“…For tirzepatide-treated participants achieving HbA1c ≤48 mmol/mol (6.5%) at 52 weeks, 75-84% sustained this until study end (median: 81 weeks). …”
-
12029
-
12030
-
12031
-
12032
-
12033
-
12034
-
12035
-
12036
-
12037
-
12038
-
12039
-
12040